Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patientsVirginie Montiel, Jean‐Luc Balligand, Leïla Belkhir et al.|EBioMedicine|2022Cited by 99
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
sTREM-1 is a specific biomarker of TREM-1 pathway activationLucie Jolly, Marc Derive, Kévin Carrasco et al.|Cellular and Molecular Immunology|2021Cited by 75
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Pierre‐François Laterre, Xavier Wittebole et al.|Intensive Care Medicine|2020Cited by 71
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trialBruno François, Pierre‐François Laterre, Simon Lambden et al.|BMJ Open|2021Cited by 20